Search Results

You are looking at 1 - 10 of 84 items for :

  • "chemotherapy" x
Clear All
Open access

Hyun-Ah Kim, Jihye Choi, Chan Sub Park, Min-Ki Seong, Sung-Eun Hong, Jae-Sung Kim, In-Chul Park, Jin Kyung Lee, Woo Chul Noh and the ASTRRA trial investigators

. Occurrence of chemotherapy-induced amenorrhoea further complicates the management of this disease. Most high-risk hormone receptor-positive breast cancer patients are treated with adjuvant chemotherapy, and 15–75% of these patients experience chemotherapy

Open access

Eric Seidel, Gudrun Walenda, Clemens Messerschmidt, Benedikt Obermayer, Mirko Peitzsch, Paal Wallace, Rohini Bahethi, Taekyeong Yoo, Murim Choi, Petra Schrade, Sebastian Bachmann, Gerhard Liebisch, Graeme Eisenhofer, Dieter Beule and Ute I Scholl

) 7 Fassnacht M Terzolo M Allolio B Baudin E Haak H Berruti A Welin S Schade-Brittinger C Lacroix A Jarzab B , Combination chemotherapy in advanced adrenocortical carcinoma . New England Journal of Medicine 2012 2189 – 2197

Open access

Luminita Nicoleta Cima, Anca Colita and Simona Fica

is approximately 50% ( 19 ). A half of the prepubertal girls treated with chemotherapy and hyper-fractionated TBI retain adequate ovarian function to enter puberty and menstruate regularly after transplantation ( 20 ). Therefore, creating a

Open access

Anne Jouinot, Bernard Royer, Etienne Chatelut, Sotheara Moeung, Guillaume Assié, Audrey Thomas-Schoemann, Jérôme Bertherat, François Goldwasser and Benoit Blanchet

administration of mitotane. The aim of this pilot study was to assess the pharmacokinetic interaction between mitotane and etoposide in ACC patients treated with mitotane and platinum-etoposide chemotherapy. Patients and methods Patients This pilot

Open access

Keina Nishio, Akiko Tanabe, Risa Maruoka, Kiyoko Nakamura, Masaaki Takai, Tatsuharu Sekijima, Satoshi Tunetoh, Yoshito Terai and Masahide Ohmichi

gynecological malignancies. Patients with these diseases generally undergo surgery that includes a bilateral oophorectomy followed by the administration of platinum-based chemotherapy in OC and EC patients, or concurrent chemo-radiation therapy (CCRT) in CC

Open access

M S Elston, V B Crawford, M Swarbrick, M S Dray, M Head and J V Conaglen

chemotherapy. Cortisol reference interval 200–700 nmol/L (shown in hatched box). (B) Dramatic ACTH response to carboplatin and etoposide chemotherapy. ACTH reference interval 2–11 pmol/L (shown in hatched box). (C) 24-h urinary free cortisol response to adrenal

Open access

Ashley K Clift, Oskar Kornasiewicz, Panagiotis Drymousis, Omar Faiz, Harpreet S Wasan, James M Kinross, Thomas Cecil and Andrea Frilling

patients with peritoneal dissemination may be considered for cytoreductive surgery and chemotherapy, or peritonectomy with hyperthermic intra-peritoneal chemotherapy (HIPEC), whilst the majority of patients with metastatic disease are treated with

Open access

Alberto Bongiovanni, Federica Recine, Flavia Foca, Valentina Fausti, Nada Riva, Greta Fabbri, Stefano Severi, Chiara Liverani, Alessandro De Vita, Chiara Spadazzi, Giacomo Miserocchi, Laura Mercatali, Dino Amadori and Toni Ibrahim

reported in <15% of cases ( 7 ). Treatment options for metastatic disease comprise liver surgery and/or locoregional and ablative therapies, somatostatin analogs, chemotherapy, targeted therapy and peptide receptor radionuclide therapy ( 8 ). Given the

Open access

Jaafar Jaafar, Eugenio Fernandez, Heba Alwan and Jacques Philippe

with ipilimumab or a BRAF inhibitor. This approval was extended in April 2015 to metastatic squamous NSCLC with progression on or after platinum-based chemotherapy. It is now approved for other cancers such as Hodgkin’s lymphoma and head and neck cancer

Open access

Kosmas Daskalakis, Marina Tsoli, Anna Angelousi, Evanthia Kassi, Krystallenia I Alexandraki, Denise Kolomodi, Gregory Kaltsas and Anna Koumarianou

, 13 ). Importantly, MTTs with everolimus and sunitinib have distinct SE profiles, which differ from those of cytotoxic chemotherapies. The continual and occasionally prolonged nature of orally administered MTT leads to new challenges in their